“PD-1 Inhibitors in Recurrent or Metastatic Oral Squamous Cell Carcinoma: Clinical Evidence, Patient Selection, and Immune-Related Toxicities”, J Oral Health Dent Ther, vol. 1, no. 1, pp. 27–31, Oct. 2026, doi: 10.68041/johdt.v1i1/06.